Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Astellas Adds To Regenerative Medicine Portfolio In Hearing Loss Deal With Frequency

Tue, 07/16/2019 - 11:05pm

Astellas adds a large-market drug candidate to its regenerative medicine portfolio, while Frequency Therapeutics almost doubles its fundraising to date...

      Related Stories 

Cipla Docks Into China, Manufacturing Plans In Tow

Tue, 07/16/2019 - 6:51pm

More Indian companies are headed to China, with Cipla the latest to seal a joint venture there, though the firm...

      Related Stories 

Deal Watch: Genentech Inks New Collaborations With Skyhawk, Convelo

Tue, 07/16/2019 - 2:38pm

Skyhawk continues its recent spate of deal-making, using its SkyStar platform in a deal with Genentech, which also is looking...

      Related Stories 

J&J US Pharma Sales Under Pressure From Pricing And Generics

Tue, 07/16/2019 - 11:26am

A 6% negative pricing impact in the US and generic Zytiga were headwinds for Johnson & Johnson's pharmaceutical business in...

      Related Stories 

Genentech Signs Up Sosei Heptares GPCR Smarts For $1bn+ Deal

Tue, 07/16/2019 - 8:57am

The companies have agreed to a multi-year, multi-target research collaboration and license deal to discover and develop medicines that modulate...

      Related Stories 

AM-Pharma Raises €116m To Finance Solo Phase III Trial

Mon, 07/15/2019 - 10:59pm

Following Pfizer’s decision not to take up an option to acquire the Dutch company, AM-Pharma has returned to the venture...

      Related Stories 

Capricor’s Interim Data Could Offer Hope For Older DMD Patients

Mon, 07/15/2019 - 2:21pm

Although only interim data from six treated patients, Capricor’s Phase II DMD study shows improvements in upper limb performance, grip...

      Related Stories 

Bayer-Natco Stivarga Infringement Case Simmers In India

Mon, 07/15/2019 - 10:30am

Bayer is battling Natco in another high-profile infringement suit in India, this time pertaining to its anticancer Stivarga (regorafenib). The...

      Related Stories 

Galapagos CEO Interview: Independence Allows Us To Keep Innovating

Mon, 07/15/2019 - 8:14am

Having signed a major alliance expansion with Gilead, Onno van Stolpe tells Scrip that any takeover talk about Galapagos would...

      Related Stories 

Pipeline Watch: Top-Line Phase III Results With Emicizumab, Lumateperone And Dabigatran

Mon, 07/15/2019 - 1:55am

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...

      Related Stories 

$5bn Galapagos Deal Won’t Be Last For Gilead, Says O’Day

Mon, 07/15/2019 - 12:48am

Handing over $5bn to Galapagos for access to several shots on the inflammation/fibrosis goal, Gilead Sciences CEO Daniel O’Day is...

      Related Stories 

Suspicions Raised Over Medytox’s Botulinum Toxin Amid Ongoing Court Battle

Sun, 07/14/2019 - 10:54pm

Shares of Korea's Medytox fell on suspicions that it supplied botulinum toxin to local hospitals before the product's approval in...

      Related Stories 

Real-World Reluctance? Despite Guidance, Drug Developers Wary Of RWE-Based Trials

Fri, 07/12/2019 - 2:13pm

Biopharma companies are reluctant to rely on real-world evidence trials, but while uncertainty remains about how these novel studies will...

      Related Stories 

Finance Watch: Among Multiple Mega-Rounds, Revolution Raises $100m For RAS Programs

Fri, 07/12/2019 - 1:31pm

Private Company Edition: Revolution Medicines follows its Sanofi partnership and Warp Drive Bio buyout with a series C venture capital...

      Related Stories 

Novartis Q2 Preview: All Eyes On New Launches

Fri, 07/12/2019 - 6:40am

The Basel-headquartered company has launched three high-profile drugs in the past couple of months. Analysts are waiting to see what...

      Related Stories 

Pages